针对神经退行性疾病的基于寡核酸的治疗方法:专注于反感性寡核酸
Heba M Mansour1, Aiman S El-Khatib2
1Central Administration of Biologicals, Innovative Products, and Clinical Studies, Egyptian Drug Authority, EDA, Giza, Egypt.
European journal of pharmacology
|March 21, 2025
概括
反感性寡核酸 (ASO) 为神经退行性疾病提供了一种新的RNA向方法. 化学修饰和输送策略是克服挑战和推进ASO疗法的关键.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 反感性寡核酸 (ASO) 是短核酸序列,旨在结合点RNA并调节蛋白质表达.
- 神经退行性疾病代表着一个重要的未满足的医疗需求,推动着寻找新的治疗方式.
- 目前的疗法往往针对下游效应,强调了针对分子水平疾病的治疗方法的需要.
研究的目的:
- 审查ASO在神经退行性疾病中的治疗潜力.
- 讨论ASO的化学修饰和作用机制.
- 总结各种神经退行性疾病的ASO治疗方法的临床前和临床发现.
主要方法:
- 科学出版物和临床试验数据的文献综述.
- 分析ASO化学修饰和输送策略的分析.
- 对脊髓肌肉缩,亨廷顿病,ALS,阿尔茨海默病和帕金森病的研究结果的综合.
主要成果:
- ASO证明了向特定RNA序列的能力,提供了一个调节源处蛋白质表达的机制.
- 已经开发出各种化学修饰和输送系统,以提高ASO的有效性和减少非目标效应.
- 临床前和临床研究表明,ASOs在治疗脊柱肌肉缩和亨廷顿病等疾病方面取得了有希望的结果.
结论:
- 基于ASO的疗法代表了治疗神经退行性疾病的有希望的策略,通过向底层RNA.
- 克服与非目标效应和输送相关的挑战对于ASO疗法的成功临床转化至关重要.
- 作为一种新的药物类别,ASO具有巨大的潜力,用于治疗衰弱的神经退行性疾病.
更多相关视频
07:47Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Published on: October 29, 2019
18.3K
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
9.4K
相关概念视频
02:30siRNA - Small Interfering RNAs
16.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.4K
01:22Alzheimer's Disease: Treatment
139
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
139
01:15Parkinson's Disease: Overview
405
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
405
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:26Alzheimer's Disease: Overview
405
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
405
01:24Parkinson's Disease: Treatment
170
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
170